Video wird geladen...
Video konnte nicht geladen werden
Pharma insider Sasha Latypova explains how "PfizerForAll" has been rebranded as "TrumpRx" and how Trump could make $500 million/year off the deal: "[Pfizer's] being forced to license Trump's name...based on previous deals...typical terms are...3-5% off wholesale revenue." For reference, Latypova notes that PfizerForAll, which appeared in the news in... show more
97,972 Aufrufe • vor 10 Monaten •via X (Twitter)
0 Kommentare
Keine Kommentare verfügbar
Kommentare vom Original-Post werden hier angezeigt
